📢Want your own personalized graphic with a summary of the structures you published in the CSD this year (Oct23-Oct24)?
Just reply with "What's my #CSDWrapped?" and tell us your publishing name.
This week only!👀
#ChemSky #CompChemSky #Crystallography #StructuralChemistry #ChemData #SmallMolecules
Just reply with "What's my #CSDWrapped?" and tell us your publishing name.
This week only!👀
#ChemSky #CompChemSky #Crystallography #StructuralChemistry #ChemData #SmallMolecules
December 10, 2024 at 3:10 PM
📢Want your own personalized graphic with a summary of the structures you published in the CSD this year (Oct23-Oct24)?
Just reply with "What's my #CSDWrapped?" and tell us your publishing name.
This week only!👀
#ChemSky #CompChemSky #Crystallography #StructuralChemistry #ChemData #SmallMolecules
Just reply with "What's my #CSDWrapped?" and tell us your publishing name.
This week only!👀
#ChemSky #CompChemSky #Crystallography #StructuralChemistry #ChemData #SmallMolecules
A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
August 4, 2025 at 2:39 PM
A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
💓 Researchers in the @josesilvalab.bsky.social used #SmallMolecules to convert mouse ESCs into embryo founder cells, which generated a complete embryo model!
Article: bit.ly/4orpbLb
Episode with discussion: bit.ly/4oTURt2
Article: bit.ly/4orpbLb
Episode with discussion: bit.ly/4oTURt2
August 26, 2025 at 4:29 PM
💓 Researchers in the @josesilvalab.bsky.social used #SmallMolecules to convert mouse ESCs into embryo founder cells, which generated a complete embryo model!
Article: bit.ly/4orpbLb
Episode with discussion: bit.ly/4oTURt2
Article: bit.ly/4orpbLb
Episode with discussion: bit.ly/4oTURt2
We have been granted a key #patent for our CRISPR-BMC genome-editing technology. This patent opens significant potential for the further commercial application of the patented nucleases. Press release: t1p.de/pbgn7 #enzyme #protein #smallmolecules #CRISPR
March 23, 2026 at 10:31 AM
We have been granted a key #patent for our CRISPR-BMC genome-editing technology. This patent opens significant potential for the further commercial application of the patented nucleases. Press release: t1p.de/pbgn7 #enzyme #protein #smallmolecules #CRISPR
Another thought-provoking #MedChem #SciComm story by Stan Van Boeckel.
On the example of Sitagliptin, he explains the power of minimizing molecules and looking for the highest ligand efficiency in #DrugDiscovery.
www.linkedin.com/posts/stan-v...
#ChemSky #ChemBio #SmallMolecules #Science #Medicines
On the example of Sitagliptin, he explains the power of minimizing molecules and looking for the highest ligand efficiency in #DrugDiscovery.
www.linkedin.com/posts/stan-v...
#ChemSky #ChemBio #SmallMolecules #Science #Medicines
Part 29 — Sometimes “smaller is elegant” in drug discovery.
In early discovery, medicinal chemists often chase potency by making molecules larger and more lipophilic. Yet potency should always be… ...
Part 29 — Sometimes “smaller is elegant” in drug discovery.
In early discovery, medicinal chemists often chase potency by making molecules larger and more lipophilic. Yet potency should always be i...
www.linkedin.com
April 25, 2026 at 6:13 AM
Another thought-provoking #MedChem #SciComm story by Stan Van Boeckel.
On the example of Sitagliptin, he explains the power of minimizing molecules and looking for the highest ligand efficiency in #DrugDiscovery.
www.linkedin.com/posts/stan-v...
#ChemSky #ChemBio #SmallMolecules #Science #Medicines
On the example of Sitagliptin, he explains the power of minimizing molecules and looking for the highest ligand efficiency in #DrugDiscovery.
www.linkedin.com/posts/stan-v...
#ChemSky #ChemBio #SmallMolecules #Science #Medicines
💡The #FDA approved 50 new drugs in 2024, 64% of which were #SmallMolecules.
Find out more about the novel drug approval trends from the past 5 years and discover the structures of the small molecule drugs that are in the CSD 👉🔗 ccdc-info.com/3WIJWWz
#Pharmaceuticals #ChemSky #BlueskyBiotech
Find out more about the novel drug approval trends from the past 5 years and discover the structures of the small molecule drugs that are in the CSD 👉🔗 ccdc-info.com/3WIJWWz
#Pharmaceuticals #ChemSky #BlueskyBiotech
January 31, 2025 at 4:57 PM
💡The #FDA approved 50 new drugs in 2024, 64% of which were #SmallMolecules.
Find out more about the novel drug approval trends from the past 5 years and discover the structures of the small molecule drugs that are in the CSD 👉🔗 ccdc-info.com/3WIJWWz
#Pharmaceuticals #ChemSky #BlueskyBiotech
Find out more about the novel drug approval trends from the past 5 years and discover the structures of the small molecule drugs that are in the CSD 👉🔗 ccdc-info.com/3WIJWWz
#Pharmaceuticals #ChemSky #BlueskyBiotech
Just 2 days left of #CSDWrapped!
Did you publish structures in the CSD this year? If so, don't miss out on getting your own personalized graphic showing your top stats for the year! #MoveOverSpotify
#ChemSky #CompChemSky #CrystalStructures #StructuralChemistry #SmallMolecules #Cheminformatics 🧪 🥽
Did you publish structures in the CSD this year? If so, don't miss out on getting your own personalized graphic showing your top stats for the year! #MoveOverSpotify
#ChemSky #CompChemSky #CrystalStructures #StructuralChemistry #SmallMolecules #Cheminformatics 🧪 🥽
📢Want your own personalized graphic with a summary of the structures you published in the CSD this year (Oct23-Oct24)?
Just reply with "What's my #CSDWrapped?" and tell us your publishing name.
This week only!👀
#ChemSky #CompChemSky #Crystallography #StructuralChemistry #ChemData #SmallMolecules
Just reply with "What's my #CSDWrapped?" and tell us your publishing name.
This week only!👀
#ChemSky #CompChemSky #Crystallography #StructuralChemistry #ChemData #SmallMolecules
December 12, 2024 at 10:29 AM
Just 2 days left of #CSDWrapped!
Did you publish structures in the CSD this year? If so, don't miss out on getting your own personalized graphic showing your top stats for the year! #MoveOverSpotify
#ChemSky #CompChemSky #CrystalStructures #StructuralChemistry #SmallMolecules #Cheminformatics 🧪 🥽
Did you publish structures in the CSD this year? If so, don't miss out on getting your own personalized graphic showing your top stats for the year! #MoveOverSpotify
#ChemSky #CompChemSky #CrystalStructures #StructuralChemistry #SmallMolecules #Cheminformatics 🧪 🥽
💊 Biologics and small molecules for psoriasis: current and future progress
Potestio et al.
@drugsincontext.bsky.social #dermatology #psoriasis #biologics #smallmolecules #pharmacology #MedSky #PharmSky
@medsky.social @me.pharmsky.app
www.drugsincontext.com/biologics-an...
Potestio et al.
@drugsincontext.bsky.social #dermatology #psoriasis #biologics #smallmolecules #pharmacology #MedSky #PharmSky
@medsky.social @me.pharmsky.app
www.drugsincontext.com/biologics-an...
November 20, 2025 at 4:10 PM
💊 Biologics and small molecules for psoriasis: current and future progress
Potestio et al.
@drugsincontext.bsky.social #dermatology #psoriasis #biologics #smallmolecules #pharmacology #MedSky #PharmSky
@medsky.social @me.pharmsky.app
www.drugsincontext.com/biologics-an...
Potestio et al.
@drugsincontext.bsky.social #dermatology #psoriasis #biologics #smallmolecules #pharmacology #MedSky #PharmSky
@medsky.social @me.pharmsky.app
www.drugsincontext.com/biologics-an...
🚨 Join us at #ASMS2025! 🚨
Catch us at Booth 208 to see SIRIUS in action — our all-in-one software for #AI -driven #StructureElucidation of #SmallMolecules.
Let’s connect, talk science, and push the boundaries of small molecule analysis.
More updates soon 👀
#SIRIUSEvents #MassSpectrometry
Catch us at Booth 208 to see SIRIUS in action — our all-in-one software for #AI -driven #StructureElucidation of #SmallMolecules.
Let’s connect, talk science, and push the boundaries of small molecule analysis.
More updates soon 👀
#SIRIUSEvents #MassSpectrometry
May 5, 2025 at 8:04 AM
🚨 Join us at #ASMS2025! 🚨
Catch us at Booth 208 to see SIRIUS in action — our all-in-one software for #AI -driven #StructureElucidation of #SmallMolecules.
Let’s connect, talk science, and push the boundaries of small molecule analysis.
More updates soon 👀
#SIRIUSEvents #MassSpectrometry
Catch us at Booth 208 to see SIRIUS in action — our all-in-one software for #AI -driven #StructureElucidation of #SmallMolecules.
Let’s connect, talk science, and push the boundaries of small molecule analysis.
More updates soon 👀
#SIRIUSEvents #MassSpectrometry
Want to learn about Ometa Flow but only have 49 seconds?
Here you go!
youtu.be/U2aAHK8ysvU?...
#discovery #smallmolecules #metabolomics
Here you go!
youtu.be/U2aAHK8ysvU?...
#discovery #smallmolecules #metabolomics
What is Ometa Flow?
YouTube video by Ometa Labs
youtu.be
April 9, 2025 at 2:36 PM
Want to learn about Ometa Flow but only have 49 seconds?
Here you go!
youtu.be/U2aAHK8ysvU?...
#discovery #smallmolecules #metabolomics
Here you go!
youtu.be/U2aAHK8ysvU?...
#discovery #smallmolecules #metabolomics
Come and speak to us about all things #peptides #smallmolecules and #medicinalchemistry at the EFMC-ASMC x International Symposium on advances in synthetic and medicinal chemistry.
#medchem #ASMC #EFMCASMC2025 #EFMC
#medchem #ASMC #EFMCASMC2025 #EFMC
September 2, 2025 at 8:23 AM
Come and speak to us about all things #peptides #smallmolecules and #medicinalchemistry at the EFMC-ASMC x International Symposium on advances in synthetic and medicinal chemistry.
#medchem #ASMC #EFMCASMC2025 #EFMC
#medchem #ASMC #EFMCASMC2025 #EFMC
Our CSO Jennifer Petter shares her expertise today as facilitator on “RNA as a Drug Target: Breakthroughs and Challenges in Small Molecule Approaches” at the 2024 Medicinal Chemistry Strategy Meeting.
#MedicinalChemistry #SmallMolecules #ExpeditionRNA #BioSky
www.linkedin.com/posts/medici...
#MedicinalChemistry #SmallMolecules #ExpeditionRNA #BioSky
www.linkedin.com/posts/medici...
Medicinal Chemistry Strategy Meeting on LinkedIn: #medicinalchemistry #rnaresearch #drugdiscovery #smallmolecules…
We are thrilled to welcome Dr. Jennifer Petter, Founder & Chief Scientific Officer of Arrakis Therapeutics, as one of the esteemed facilitators at the…
www.linkedin.com
November 13, 2024 at 4:43 PM
Our CSO Jennifer Petter shares her expertise today as facilitator on “RNA as a Drug Target: Breakthroughs and Challenges in Small Molecule Approaches” at the 2024 Medicinal Chemistry Strategy Meeting.
#MedicinalChemistry #SmallMolecules #ExpeditionRNA #BioSky
www.linkedin.com/posts/medici...
#MedicinalChemistry #SmallMolecules #ExpeditionRNA #BioSky
www.linkedin.com/posts/medici...
Novartis acquires the rights to PTC518, a splicing modifier targeting Huntington’s disease, in a $2.9B deal with PTC Thx. Early studies show it reduces mutant huntingtin protein levels effectively. pubmed.ncbi.nlm.nih.gov/39155237/
#HuntingtonsDisease #PharmaNews #DrugDevelopment
#SmallMolecules
#HuntingtonsDisease #PharmaNews #DrugDevelopment
#SmallMolecules
Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first-in-human study - PubMed
PTC518 was well tolerated, and proof of mechanism of this novel splicing modifier was demonstrated by the dose-dependent decrease in systemic HTT mRNA and HTT protein levels. Results from this first-i...
pubmed.ncbi.nlm.nih.gov
December 3, 2024 at 10:31 PM
Novartis acquires the rights to PTC518, a splicing modifier targeting Huntington’s disease, in a $2.9B deal with PTC Thx. Early studies show it reduces mutant huntingtin protein levels effectively. pubmed.ncbi.nlm.nih.gov/39155237/
#HuntingtonsDisease #PharmaNews #DrugDevelopment
#SmallMolecules
#HuntingtonsDisease #PharmaNews #DrugDevelopment
#SmallMolecules
On Monday we published an article on Phase I clinical trial design.
#PhaseI #ClinicalResearch #DrugDevelopment #Biomarker #SmallMolecules #CRO #Pharma
genelifecr.blogspot.com/2026/09/phas...
#PhaseI #ClinicalResearch #DrugDevelopment #Biomarker #SmallMolecules #CRO #Pharma
genelifecr.blogspot.com/2026/09/phas...
Phase I Clinical Trials: The Most Consequential Studies in Drug Development
Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis
genelifecr.blogspot.com
September 11, 2026 at 10:29 AM
On Monday we published an article on Phase I clinical trial design.
#PhaseI #ClinicalResearch #DrugDevelopment #Biomarker #SmallMolecules #CRO #Pharma
genelifecr.blogspot.com/2026/09/phas...
#PhaseI #ClinicalResearch #DrugDevelopment #Biomarker #SmallMolecules #CRO #Pharma
genelifecr.blogspot.com/2026/09/phas...
The #pharmaceutical industry's best new drugs may already exist.
Sildenafil. Thalidomide. Nitisinone.
Drug repurposing isn't a shortcut — it's a head start. Safety known. PK established. Manufacturing exists.
#DrugRepurposing #ClinicalResearch #SmallMolecules #Pharma
Sildenafil. Thalidomide. Nitisinone.
Drug repurposing isn't a shortcut — it's a head start. Safety known. PK established. Manufacturing exists.
#DrugRepurposing #ClinicalResearch #SmallMolecules #Pharma
Drug Repurposing: Why the Pharmaceutical Industry's Best New Drugs May Already Exist
Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis
genelifecr.blogspot.com
August 25, 2026 at 4:51 AM
The #pharmaceutical industry's best new drugs may already exist.
Sildenafil. Thalidomide. Nitisinone.
Drug repurposing isn't a shortcut — it's a head start. Safety known. PK established. Manufacturing exists.
#DrugRepurposing #ClinicalResearch #SmallMolecules #Pharma
Sildenafil. Thalidomide. Nitisinone.
Drug repurposing isn't a shortcut — it's a head start. Safety known. PK established. Manufacturing exists.
#DrugRepurposing #ClinicalResearch #SmallMolecules #Pharma
What AI did in Rentosertib's development:
→ Identified TNIK as a novel IPF target in months, not years → Generated and optimized the molecular structure → Compressed discovery from 4–6 years to 18 months
#AI #DrugDiscovery #ClinicalResearch #SmallMolecules #Rentosertib #Pharma #CRO
→ Identified TNIK as a novel IPF target in months, not years → Generated and optimized the molecular structure → Compressed discovery from 4–6 years to 18 months
#AI #DrugDiscovery #ClinicalResearch #SmallMolecules #Rentosertib #Pharma #CRO
The First AI-Designed Drug Just Entered Phase III. Here Is What It Changes — and What It Doesn't.
Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis
genelifecr.blogspot.com
August 23, 2026 at 12:00 PM
What AI did in Rentosertib's development:
→ Identified TNIK as a novel IPF target in months, not years → Generated and optimized the molecular structure → Compressed discovery from 4–6 years to 18 months
#AI #DrugDiscovery #ClinicalResearch #SmallMolecules #Rentosertib #Pharma #CRO
→ Identified TNIK as a novel IPF target in months, not years → Generated and optimized the molecular structure → Compressed discovery from 4–6 years to 18 months
#AI #DrugDiscovery #ClinicalResearch #SmallMolecules #Rentosertib #Pharma #CRO
The first AI-designed drug just entered Phase III.
Rentosertib — target identified by AI, molecule generated by AI, #ClinicalTrial designed and executed by humans.
That last part matters more than most of the AI-in-pharma coverage acknowledges.
#DrugDiscovery #AI #SmallMolecules #Pharma
Rentosertib — target identified by AI, molecule generated by AI, #ClinicalTrial designed and executed by humans.
That last part matters more than most of the AI-in-pharma coverage acknowledges.
#DrugDiscovery #AI #SmallMolecules #Pharma
The First AI-Designed Drug Just Entered Phase III. Here Is What It Changes — and What It Doesn't.
Genelife, Clinical Research, GCP, Medical Device, Patient Recruitment, Asthma, Oncology, Ophthalmology, Clinical Trials, Cancer, tuberculosis
genelifecr.blogspot.com
August 18, 2026 at 6:31 AM
The first AI-designed drug just entered Phase III.
Rentosertib — target identified by AI, molecule generated by AI, #ClinicalTrial designed and executed by humans.
That last part matters more than most of the AI-in-pharma coverage acknowledges.
#DrugDiscovery #AI #SmallMolecules #Pharma
Rentosertib — target identified by AI, molecule generated by AI, #ClinicalTrial designed and executed by humans.
That last part matters more than most of the AI-in-pharma coverage acknowledges.
#DrugDiscovery #AI #SmallMolecules #Pharma
Because this protein plays a key role in inflammation, finding a targetable pocket is an important first step toward developing more effective therapies for autoimmune diseases and cancer.
#Proteomics #SmallMolecules #Therapeutics #Research
4/4
#Proteomics #SmallMolecules #Therapeutics #Research
4/4
August 17, 2026 at 12:18 PM
Because this protein plays a key role in inflammation, finding a targetable pocket is an important first step toward developing more effective therapies for autoimmune diseases and cancer.
#Proteomics #SmallMolecules #Therapeutics #Research
4/4
#Proteomics #SmallMolecules #Therapeutics #Research
4/4
An Aggregation Advisor for Ligand Discovery #modeling #protein #ligand #interaction #prediction #smallmolecules #vhts #gigascale #docking
March 21, 2025 at 8:53 AM
Virtual screening. Validated. #modeling #protein #ligand #interaction #prediction #smallmolecules #vhts #gigascale #docking
March 21, 2025 at 8:53 AM
🌟 Join Us at the Agilent Forum Analytik 🌟
Don’t miss Martin Hoffmann’s talk on #SmallMoleculeIdentification with #SIRIUSSoftware.
🗓 12 Feb, 9:40 AM
📍 BOKU Vienna
🎟️ Free attendance—register by 31 Jan!
See you in Vienna!
#AgilentForum #MassSpectrometry #SmallMolecules #SIRIUSEvents
Don’t miss Martin Hoffmann’s talk on #SmallMoleculeIdentification with #SIRIUSSoftware.
🗓 12 Feb, 9:40 AM
📍 BOKU Vienna
🎟️ Free attendance—register by 31 Jan!
See you in Vienna!
#AgilentForum #MassSpectrometry #SmallMolecules #SIRIUSEvents
January 22, 2025 at 11:02 AM
🌟 Join Us at the Agilent Forum Analytik 🌟
Don’t miss Martin Hoffmann’s talk on #SmallMoleculeIdentification with #SIRIUSSoftware.
🗓 12 Feb, 9:40 AM
📍 BOKU Vienna
🎟️ Free attendance—register by 31 Jan!
See you in Vienna!
#AgilentForum #MassSpectrometry #SmallMolecules #SIRIUSEvents
Don’t miss Martin Hoffmann’s talk on #SmallMoleculeIdentification with #SIRIUSSoftware.
🗓 12 Feb, 9:40 AM
📍 BOKU Vienna
🎟️ Free attendance—register by 31 Jan!
See you in Vienna!
#AgilentForum #MassSpectrometry #SmallMolecules #SIRIUSEvents
High-quality datasets are key for reliable #MachineLearning in #AnalyticalChemistry!
We explain:
✨ Why diverse datasets matter for SIRIUS
✨ The Importance of representing all #SmallMolecules
✨ Which tools help assessing #DataQuality
bright-giant.com/2025/01/20/m...
#SIRIUSBackground #AI
We explain:
✨ Why diverse datasets matter for SIRIUS
✨ The Importance of representing all #SmallMolecules
✨ Which tools help assessing #DataQuality
bright-giant.com/2025/01/20/m...
#SIRIUSBackground #AI
January 22, 2025 at 8:46 AM
High-quality datasets are key for reliable #MachineLearning in #AnalyticalChemistry!
We explain:
✨ Why diverse datasets matter for SIRIUS
✨ The Importance of representing all #SmallMolecules
✨ Which tools help assessing #DataQuality
bright-giant.com/2025/01/20/m...
#SIRIUSBackground #AI
We explain:
✨ Why diverse datasets matter for SIRIUS
✨ The Importance of representing all #SmallMolecules
✨ Which tools help assessing #DataQuality
bright-giant.com/2025/01/20/m...
#SIRIUSBackground #AI